Evaluation of pulmonary absorption using pharmacokinetic methods

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 14, Issue SUPPL. 1, 2001, Pages

  Derendorf, H ^a   Hochhaus, G ^a   Mollmann H ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Inhalation; Lung; Pharmacokinetics; Therapy

Indexed keywords

BUDESONIDE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; SALBUTAMOL; TRIAMCINOLONE ACETONIDE;

ASTHMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EXCRETION; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; HUMAN; LUNG; REVIEW;

EID: 0035115533     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680150506295     Document Type: Review

References (33)

1. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline
2. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
3. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI
4. Determination of the relative bioavailability of salbutamol to the lung following inhalation
5. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler
6. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices
7. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration
8. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids
9. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety
10. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects
11. Pharmacology of fluticasone propionate
12. Oral bioavailability of fluticasone propionate in healthy subjects
13. The human pharmacology of fluticasone propionate
14. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects
15. New method for calculating the intrinsic absorption rate of drugs
16. Pulmonary disposition of the potent glucocorticoid budesonide, evaluated in an isolated perfused rat lung model
17. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms
18. Scintigraphic assessment of therapeutic aerosols
19. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler
20. Pulmonary deposition of inhaled terbutaline: Comparison of scanning gamma camera and urinary excretion methods
21. Understanding regional lung deposition data in gamma scintigraphy
22. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer
23. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices
24. Basis of airway selectivity of inhaled glucocorticoids
25. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model
26. Pulmonary targeting of liposomal triamcinolone acetonide phosphate
27. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate
28. Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats
29. Pharmacokinetics of fluticasone propionate inhaled from Diskhaler® and Diskus® powder devices in asthmatic patients
30. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus after repeat doses in healthy subjects and asthmatic patients
31. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma
32. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year
33. The use of Ludep as a tool in the prediction of total and regional lung deposition: Advantages, limitations and possible developments of the package